Anti-HER2-ADC: Phase I started

Synthon began a 2-part, open-label, international Phase I trial of IV SYD985 every

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE